Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Triple Hormone Receptor Agonism: GLP-1, GIP, and Glucagon Pathways Retatrutide combines GLP-1-mediated appetite suppression and insulin secretion, GIP-enhanced glycaemic benefit, and glucagon receptor-driven energy expenditure and hepatic fat oxidation into a single pharmacological profile
GLP-1 agonists reduce insulin levels, and lower insulin triggers the kidneys to release stored sodium and water
Adults without diabetes saw average weight loss of 15% to 20.9% depending on dosage, compared to 3.1% for people on a placebo
This is not accidental
US$ 24.19
US$ 22.89
